The results suggested that there is a strong association between rs4143815 C > G and the cancer risks (G vs. C: OR = 1.386, 95% CI: 1.132-1.696, p = 0.002; GG vs. CG + CC: OR = 1.843 95% CI: 1.300-2.613, p = 0.002; GG + CG vs. CC: OR = 1.280, 95% CI: 1.040-1.576, p = 0.020).
The results suggested that there is a strong association between rs41</span>43815 C > G and the cancer risks (G vs. C: OR = 1.386, 95% CI: 1.132-1.696, p = 0.002; GG vs. CG + CC: OR = 1.843 95% CI: 1.300-2.613, p = 0.002; GG + CG vs. CC: OR = 1.280, 95% CI: 1.040-1.576, p = 0.020).
In conclusions, the results of this meta-analysis have revealed an association between <i>PD-1</i> rs2227981, rs11568821, rs7421861, as well as <i>PD-L1</i> rs4143815 polymorphisms and overall cancer susceptibility.
In conclusions, the results of this meta-analysis have revealed an association between <i>PD-1</i> rs2227981, rs11568821, rs7421861, as well as <i>PD-L1</i> rs4143815 polymorphisms and overall cancer susceptibility.
Our results indicate that rs4143815 of PD-L1 is significantly associated with T1DM and may serve as a new biomarker to predict the T1DM susceptibility.
In addition, the CGG haplotype in PD-L1 associated with T1D</span> (constructed from rs822342, rs2297137 and rs4143815 polymorphisms) showed an OR = 1.44 [1.08 to 1.93].
We evaluated the frequency of alleles and genotypes of <i>IL-10</i> (rs3024496, rs1800872), <i>IL-10RA</i> (rs3135932), <i>IL-10RB</i> (rs2834167), <i>PD-1</i> (rs2227982, rs10204525), <i>PD-L1</i> (rs4143815), <i>PD-L2</i> (rs7854413), and single-nucleotide polymorphisms (SNPs) in 103 patients with chronic pathology (CP), such as elephantiasis or hydrocele and 106 endemic normal (EN) individuals from a South Indian population living in an area endemic for LF.
We evaluated the frequency of alleles and genotypes of <i>IL-10</i> (rs3024496, rs1800872), <i>IL-10RA</i> (rs3135932), <i>IL-10RB</i> (rs2834167), <i>PD-1</i> (rs2227982, rs10204525), <i>PD-L1</i> (rs4143815), <i>PD-L2</i> (rs7854413), and single-nucleotide polymorphisms (SNPs) in 103 patients with chronic pathology (CP), such as elephantiasis or hydrocele and 106 endemic normal (EN) individuals from a South Indian population living in an area endemic for LF.
A polymorphism in the <i>PDL1</i> gene (rs4143815) was the unique potential genetic variant of 10 year BCR (training set: <i>p</i> = 0.003, HR (95% CI) = 0.58 (0.41-0.83); replication set: <i>p</i> = 0.063, HR (95% CI) = 0.52 (0.26-1.04)) that was significantly associated with 5 year BCR (training set: <i>p</i> = 0.009, HR (95% CI) = 0.59 (0.40-0.88); replication set: <i>p</i> = 0.036, HR (95% CI) = 0.39 (0.16-0.94)).No biomarkers of OS were replicated. rs4143815-<i>PDL1</i> arose as a new immunogenetic biomarker of BCR in PCa, giving new insights into the RT/immune system interaction, which could be potentially useful in new approaches using anti-PDL1 therapies for PCa.
Subgroup analysis based on cancer type suggested that PD-L1 rs4143815 C > G might increase the susceptibility to gastric cancer (G vs. C: OR = 1.842, 95% CI: 1.403-2.418, p < 0.001) and bladder cancer (G vs. C: OR = 2.015, 95% CI: 1.556-2.608, p < 0.001), and genotype GG carriers of PD-L1 rs4143815 C > G might have higher risks of HCC (GG vs. CG + CC: OR = 2.226 95% CI: 1.562-3.172, p < 0.001).
A polymorphism in the <i>PDL1</i> gene (rs4143815) was the unique potential genetic variant of 10 year BCR (training set: <i>p</i> = 0.003, HR (95% CI) = 0.58 (0.41-0.83); replication set: <i>p</i> = 0.063, HR (95% CI) = 0.52 (0.26-1.04)) that was significantly associated with 5 year BCR (training set: <i>p</i> = 0.009, HR (95% CI) = 0.59 (0.40-0.88); replication set: <i>p</i> = 0.036, HR (95% CI) = 0.39 (0.16-0.94)).No biomarkers of OS were replicated. rs4143815-<i>PDL1</i> arose as a new immunogenetic biomarker of BCR in PCa, giving new insights into the RT/immune system interaction, which could be potentially useful in new approaches using anti-PDL1 therapies for PCa.
Subgroup analysis based on cancer type suggested that PD-L1 rs4143815 C > G might increase the susceptibility to gastric cancer (G vs. C: OR = 1.842, 95% CI: 1.403-2.418, p < 0.001) and bladder cancer (G vs. C: OR = 2.015, 95% CI: 1.556-2.608, p < 0.001), and genotype GG carriers of PD-L1 rs4143815 C > G might have higher risks of HCC (GG vs. CG + CC: OR = 2.226 95% CI: 1.562-3.172, p < 0.001).
We evaluated the frequency of alleles and genotypes of <i>IL-10</i> (rs3024496, rs1800872), <i>IL-10RA</i> (rs3135932), <i>IL-10RB</i> (rs2834167), <i>PD-1</i> (rs2227982, rs10204525), <i>PD-L1</i> (rs4143815), <i>PD-L2</i> (rs7854413), and single-nucleotide polymorphisms (SNPs) in 103 patients with chronic pathology (CP), such as elephantiasis or hydrocele and 106 endemic normal (EN) individuals from a South Indian population living in an area endemic for LF.
Subgroup analysis based on cancer type suggested that PD-L1 rs4143815 C > G might increase the susceptibility to gastric cancer (G vs. C: OR = 1.842, 95% CI: 1.403-2.418, p < 0.001) and bladder cancer (G vs. C: OR = 2.015, 95% CI: 1.556-2.608, p < 0.001), and genotype GG carriers of PD-L1 rs4143815 C > G might have higher risks of HCC (GG vs. CG + CC: OR = 2.226 95% CI: 1.562-3.172, p < 0.001).
Subgroup analysis based on cancer type suggested that PD-L1 rs4143815 C > G might increase the susceptibility to gastric cancer (G vs. C: OR = 1.842, 95% CI: 1.403-2.418, p < 0.001) and bladder cancer (G vs. C: OR = 2.015, 95% CI: 1.556-2.608, p < 0.001), and genotype GG carriers of PD-L1 rs4143815 C > G might have higher risks of HCC (GG vs. CG + CC: OR = 2.226 95% CI: 1.562-3.172, p < 0.001).
Subgroup analysis based on cancer type suggested that PD-L1 rs4143815 C > G might increase the susceptibility to gastric cancer (G vs. C: OR = 1.842, 95% CI: 1.403-2.418, p < 0.001) and bladder cancer (G vs. C: OR = 2.015, 95% CI: 1.556-2.608, p < 0.001), and genotype GG carriers of PD-L1 rs4143815 C > G might have higher risks of HCC (GG vs. CG + CC: OR = 2.226 95% CI: 1.562-3.172, p < 0.001).
Our results indicated that three functional polymorphisms (rs2297136, rs4143815 and rs17718883) of the PD-L1 gene were associated with HCC risk and prognosis, suggesting that genetic variants of PD-L1 polymorphisms might be a possible prognostic marker for the prediction of HCC risk and development.
Data revealed that the rs2297136 (C > T) SNP TT (p = 0.03) and rs4143815 (C > G) SNP GG genotypes (p < 0.001) were associated with significantly increased risks of HCC.
No association was found between rs2890658 (A > C) SNP and HCC risk and this risk was significantly decreased in individuals with the rs17718883 SNP CG + GG genotype (p < 0.001).